Literature DB >> 22420244

Studies on in vitro hemolysis and utility of corrective formulas for reporting results on hemolyzed specimens.

Giuseppe Lippi1, Paola Avanzini, Fernanda Pavesi, Mirco Bardi, Luigi Ippolito, Rosalia Aloe, Emmanuel J Favaloro.   

Abstract

INTRODUCTION: Spuriously hemolyzed specimens are the most common preanalytical problems in clinical laboratories. Corrective formulas have been proposed to allow the laboratory to release test results on these specimens. This study aimed to assess the influence of spurious hemolysis and reliability of corrective formulas.
MATERIALS AND METHODS: Blood collected into lithium heparin vacuum tubes was divided in aliquots and subjected to mechanical injury by aspiration with an insulin syringe equipped with a thin needle (30 gauge). Each aliquot (numbered from "#0" to "#5") was subjected to a growing number of passages through the needle, from 0 to 5 times. After hematological testing, plasma was separated by centrifugation and assayed for lactate dehydrogenase (LD), aspartate aminotransferase (AST), potassium and hemolysis index (HI).
RESULTS: Cell-free hemoglobin concentration gradually increased from aliquot #0 (HI: 0) to #5 (HI: 76 +/- 22, cell-free hemoglobin approximately 37.0 g/L). A highly significant inverse correlation was observed between HI and red blood cell count (RBC), hematocrit, mean corpuscular volume (MCV), LD, AST, potassium, whereas the correlation was negative with mean corpuscular hemoglobin (MCH). No correlation was found with hemoglobin, platelet count and glucose. A trend towards decrease was also observed for white blood cells count. The ANCOVA comparison of analyte-specific regression lines from the five subjects studied revealed significant differences for all parameters except potassium. In all circumstances the sy,x of these equations however exceeded the allowable clinical bias.
CONCLUSIONS: Mechanical injury of blood, as it might arise from preanalytical problems, occurs dishomogeneously, so that corrective formulas are unreliable and likely misleading.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22420244     DOI: 10.11613/bm.2011.040

Source DB:  PubMed          Journal:  Biochem Med (Zagreb)        ISSN: 1330-0962            Impact factor:   2.313


  7 in total

1.  The effect of hemolysis on quality control metrics for noninvasive prenatal testing.

Authors:  Yaya Guo; Dandan Yu; Kaisu Zhou; Jie Wang; Dongzhu Lei; Zhenpeng Xu; Weijiang Tang; Miaofeng Wu; Xingxing Fang; Jiankun Shen; Zhiyu Peng; Jiale Xiang
Journal:  BMC Med Genomics       Date:  2022-06-04       Impact factor: 3.622

2.  Effect of Blood Cell Subtypes Lysis on Routine Biochemical Tests.

Authors:  Burcu Ünlü; Tuncay Küme; Mestan Emek; Murat Örmen; Yavuz Doğan; Ali Rıza Şişman; Gül Ergör; Canan Çoker
Journal:  J Med Biochem       Date:  2018-01-01       Impact factor: 3.402

Review 3.  Hemolyzed Specimens: Major Challenge for Identifying and Rejecting Specimens in Clinical Laboratories.

Authors:  Wan Norlina Wan Azman; Julia Omar; Tan Say Koon; Tuan Salwani Tuan Ismail
Journal:  Oman Med J       Date:  2019-03

4.  Reduction of gross hemolysis in catheter-drawn blood using Greiner Holdex tube holder.

Authors:  Giuseppe Lippi; Paola Avanzini; Rosalia Aloe; Gianfranco Cervellin
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

5.  Evaluation of sample hemolysis in blood collected by S-Monovette using vacuum or aspiration mode.

Authors:  Giuseppe Lippi; Paola Avanzini; Roberta Musa; Franca Sandei; Rosalia Aloe; Gianfranco Cervellin
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

Review 6.  Critical review and meta-analysis of spurious hemolysis in blood samples collected from intravenous catheters.

Authors:  Giuseppe Lippi; Gianfranco Cervellin; Camilla Mattiuzzi
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

7.  Preanalytical phase--a continuous challenge for laboratory professionals.

Authors:  Ana-Maria Simundic; Giuseppe Lippi
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.